Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study.

Raffaele NapoliCesare BerraAndrei-Mircea CatarigChiara Di LoretoEmily DonatielloTina Landsvig BerentzenDario PitoccoFrancesco Giorgino

Published in: Diabetes, obesity & metabolism (2023)

In routine clinical practice in Italy, patients with T2D treated with once-weekly semaglutide for 30 weeks achieved clinically significant improvements in HbA1c, body weight and other outcomes.

Keyphrases

body weight
clinical practice
electronic health record
big data
data analysis